论文部分内容阅读
目的:探讨ER、PR与C-erbB-2在乳腺癌中的表达及相关性。方法:采用免疫组织化学SP法对79例乳腺癌和14例乳腺良性病变进行ER、PR、C-erbB-2的表达进行检测。结果:乳腺癌中的ER、PR、C-erbB-2阳性率分别为52·7%,47·3%,30·9%。ER、PR、C-erbB-2的表达与乳腺癌的组织类型、分化程度具有相关性;ER、PR在所有良性病变、低度恶性肿瘤中表达水平较高,在浸润癌、有淋巴结和全身转移的肿瘤中表达水平较低;C-erbB-2在所有良性病变中呈阴性表达,在低度恶性肿瘤中表达水平较低,在浸润癌、有淋巴结和全身转移的肿瘤中表达水平较高;ER、PR与C-erbB-2、表达之间均存在负相关。结论:ER、PR、C-erbB-2的检测对乳腺癌治疗方案的制定和预后估计有重要意义。
Objective: To investigate the expression and correlation of ER, PR and C-erbB-2 in breast cancer. Methods: The expressions of ER, PR and C-erbB-2 in 79 cases of breast cancer and 14 cases of benign breast lesions were detected by immunohistochemical SP method. Results: The positive rates of ER, PR and C-erbB-2 in breast cancer were 52.7%, 47.3% and 30.9% respectively. The expression of ER, PR and C-erbB-2 was correlated with the histological type and differentiation of breast cancer. The expression of ER and PR was higher in all benign and low-grade malignant tumors. In invasive carcinoma, with lymph node and whole body The expression level of C-erbB-2 was negative in all benign lesions, lower in low-grade malignant tumors and higher in invasive carcinoma, lymph node-associated tumors and systemic metastasis There was a negative correlation between ER, PR and C-erbB-2 expression. Conclusion: The detection of ER, PR and C-erbB-2 is of great significance for the development of prognosis and prognosis of breast cancer.